In the relentless quest to understand and conquer cancer, researchers have honed in on a new molecular frontier—Coenzyme Q10 (CoQ10) oxidoreductases and their pivotal role in ferroptosis, a unique form of programmed cell death distinguished by iron-dependent lipid peroxidation. The insight uncovered by Lee, Yoo, Kim, and colleagues, published in the June 2026 issue of Experimental & Molecular Medicine, unveils a complex interplay between redox homeostasis, cancer cell survival, and ferroptotic susceptibility, promising innovative therapeutic avenues that could revolutionize oncology.

CoQ10, a lipophilic molecule embedded within the inner mitochondrial membrane, functions fundamentally as an electron carrier in the mitochondrial respiratory chain. However, emerging evidence positions CoQ10 oxidoreductases as critical modulators of redox balance, influencing a cell’s propensity to undergo ferroptosis. Ferroptosis is characterized by iron-driven accumulation of lipid-based reactive oxygen species (ROS), disrupting cellular membranes and leading to an oxidative demise distinct from apoptosis or necrosis. This pathway has garnered attention for its potential to selectively target cancer cells resistant to conventional apoptosis-inducing therapies.

The research team deciphers how CoQ10 oxidoreductases exert a finely-tuned redox regulation, effectively governing ferroptotic sensitivity. These enzymes catalyze the reduction of CoQ10, sustaining its antioxidant capacity to mitigate lipid peroxidation. Intriguingly, certain cancers exhibit dysregulated expression or activity of these oxidoreductases, skewing the redox balance and fostering resistance against ferroptotic triggers. This mechanistic insight deepens our understanding of how cancer cells adapt to oxidative stress, potentially exploiting CoQ10 pathways to evade death.

A central revelation from the study is how CoQ10 oxidoreductase activity functions not only as a metabolic safeguard but also as a regulatory nexus controlling lipid peroxide detoxification. By reducing CoQ10, these enzymes replenish ubiquinol pools—powerful chain-breaking antioxidants that inhibit the propagation of lipid radicals in membranes. This antioxidative shield forms a biochemical barrier against ferroptotic induction, supporting cancer cell survival amid fluctuating oxidative milieus.

Ferroptosis has emerged as a compelling alternative to traditional apoptosis-centered therapies, particularly in malignancies exhibiting refractory resistance or mutated apoptotic machinery. The modulation of CoQ10 oxidoreductases, therefore, uncovers a therapeutic opportunity to sensitize tumors to ferroptotic death. Pharmacological inhibition or genetic suppression of these enzymes could dismantle the antioxidative defenses, augmenting lipid peroxidation and tipping the scales toward ferroptosis. Such strategies may offer a precision oncology approach, exploiting metabolic vulnerabilities while sparing normal tissues.

Adding complexity, the study highlights the context-dependent roles of different CoQ10 oxidoreductases isoforms across various cancer types. Some enzymes are upregulated, conferring enhanced ferroptosis resistance, whereas others might paradoxically promote oxidative stress under specific metabolic states. This heterogeneity accentuates the necessity for tailored therapeutic designs considering tumor-specific redox landscapes and CoQ10 enzymatic profiles.

Moreover, the researchers explore the cross-talk between CoQ10 oxidoreductases and other ferroptosis regulators, such as glutathione peroxidase 4 (GPX4) and membrane lipid remodeling enzymes. Inhibitory effects on CoQ10 oxidoreductases synergize with GPX4-targeting agents, generating combinatorial lethality that dismantles both lipid peroxide scavenging and detoxification pathways. This dual targeting could overcome resistance mechanisms and potentiate ferroptotic responses in challenging cancer subtypes.

Beyond its anti-ferroptotic functions, CoQ10 reduction by these oxidoreductases indirectly influences mitochondrial bioenergetics and ROS generation, highlighting an intricate feedback loop intertwining metabolic flux and redox signaling. As cancer cells often rewire mitochondrial dynamics to fuel aggressive phenotypes, manipulating CoQ10 oxidoreductase activity could disrupt cellular energetics, further sensitizing tumors to ferroptotic death.

The therapeutic implications of these findings are manifold. Small molecules modulating CoQ10 oxidoreductase activity offer a promising class of anticancer agents. Currently, several inhibitors are in preclinical evaluation, aiming to destabilize ubiquinol regeneration and collapse cellular redox defenses. Nanotechnology-enhanced delivery systems engineered to target tumors could also enhance drug specificity, reducing off-target effects and oxidative toxicity to healthy tissues.

Translationally, the elucidation of CoQ10 oxidoreductases as ferroptosis gatekeepers may provide prognostic biomarkers for patient stratification. Expression levels or enzymatic activity profiles could predict tumor susceptibility to ferroptosis-inducing therapies, enabling more personalized treatment regimens. Additionally, monitoring redox metabolites derived from CoQ10 pathways may serve as dynamic markers of therapeutic response.

Despite these advances, challenges remain in fully deciphering the intricate regulation of ferroptosis by CoQ10 oxidoreductases. Tumor microenvironment factors such as hypoxia, nutrient availability, and iron metabolism intricately modulate ferroptotic outcomes and CoQ10 enzyme function. Future studies must integrate multi-omic and spatial profiling to map these interactions comprehensively, paving the way for sophisticated intervention strategies.

In conclusion, the pioneering work of Lee and colleagues spotlights CoQ10 oxidoreductases as critical arbiters of ferroptotic cell death in cancer, functioning through redox regulation of lipid peroxide detoxification and cellular bioenergetics. Their dual role in shielding tumor cells and offering a therapeutic Achilles’ heel heralds a new chapter in redox biology and cancer therapy. As ferroptosis-based interventions advance toward clinical reality, targeting CoQ10 oxidoreductases emerges as a promising strategy to overcome drug resistance and improve patient outcomes in the relentless battle against cancer.

The implications of these findings extend beyond oncology, potentially informing therapeutic approaches for other diseases characterized by dysregulated redox homeostasis and lipid peroxidation, including neurodegeneration and cardiovascular disorders. The nuanced understanding of CoQ10 oxidoreductase function thus heralds broader biomedical significance, representing a cornerstone of future redox medicine.

Subject of Research:
CoQ10 oxidoreductases in ferroptosis regulation and cancer therapy

Article Title:
CoQ₁₀ oxidoreductases in ferroptosis and cancer: redox regulation and therapeutic opportunities.

Article References:
Lee, J., Yoo, I., Kim, M. et al. CoQ₁₀ oxidoreductases in ferroptosis and cancer: redox regulation and therapeutic opportunities. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01736-w

Image Credits: AI Generated

DOI: 03 June 2026

In a landmark study conducted at the Icahn School of Medicine at Mount Sinai, researchers have revealed a previously undetected drug-binding pocket within PKMYT1, a kinase intimately involved in cell cycle regulation and cancer progression. This groundbreaking discovery not only challenges current understanding of the protein’s structural dynamics but also underscores both the promise and inherent limitations of contemporary artificial intelligence (AI) methods in the field of drug discovery.

Kinases like PKMYT1 orchestrate critical cellular processes such as growth and division, rendering them prime candidates for therapeutic targeting in oncology. Traditionally, drug development strategies against kinases have centered on the ATP-binding site, which is essential for their catalytic function. However, the ATP-binding motifs among kinases exhibit high degrees of conservation, complicating efforts to engineer drugs with high specificity. This often results in off-target effects that can diminish clinical effectiveness and elevate toxicity risks.

By leveraging a synergistic approach that combined AI-based protein modeling with experimental validation, the researchers uncovered a novel allosteric pocket on PKMYT1. Notably, this binding site escaped detection by leading AI platforms, including the widely acclaimed AlphaFold2. This hidden pocket presents a unique avenue for more selective drug design, diverging from the conventional ATP-competitive strategies and heralding a new paradigm in kinase inhibition.

The research unveiled that PKMYT1 exhibits pronounced conformational flexibility, oscillating between distinct shapes rather than maintaining a static structure. Such dynamic behavior implicates the existence of transient binding pockets that evade prediction by current computational models. These transient pockets might serve as ‘Achilles’ heels’ for selective inhibitor binding, a concept with profound implications for drug discovery beyond this single protein.

Experimentally, the team employed X-ray crystallography and biochemical assays to corroborate binding interactions and validate the biological implications of their findings. Complementing these traditional methods, molecular dynamics simulations and advanced AI models like AlphaFold3 and Boltz-2 were utilized to explore whether computational tools could retrospectively predict the discovered binding modes, exposing gaps in present-day AI predictive capability.

A particularly striking revelation was the sensitivity of the protein-ligand interaction to minuscule chemical modifications. Slight changes in the molecular structure of candidate compounds dramatically altered their binding site preference, toggling between the newfound hidden pocket and more canonical sites. This sensitivity reflects the intricate nature of protein-ligand recognition and underscores the necessity for meticulous experimental validation alongside in silico predictions.

The dual leadership of the study, Professors Avner Schlessinger and Michael Lazarus, highlights a balanced perspective on AI’s role. While AI tools excel at confirming known structural patterns, they may falter in uncovering novel or cryptic sites, especially in proteins that are inherently flexible. This work emphasizes that experimental inquiry remains indispensable, even as AI transforms biomedical research.

From a translational perspective, the discovery of this new druggable site opens exciting therapeutic possibilities. By designing inhibitors that selectively target this unique allosteric pocket, drug developers may circumvent the specificity and toxicity challenges endemic to existing kinase inhibitors. This could potentially accelerate the development of next-generation cancer therapies with improved efficacy and safety profiles.

Moreover, these findings serve as a wake-up call for the AI drug discovery community. The inability of cutting-edge AI platforms to predict the full spectrum of protein conformations spotlights areas for computational innovation, particularly in modeling protein plasticity and allostery. Enhanced algorithms, informed by experimental data like this study’s insights, may soon enable more comprehensive structural predictions with direct impacts on drug development strategies.

Looking ahead, the research team plans to advance the chemical optimization of lead compounds that engage the hidden PKMYT1 pocket with greater potency and selectivity. Concurrently, they aim to survey a broader array of cancer-associated kinases for similar cryptic sites, potentially revealing a wider landscape of novel therapeutic targets across the kinome.

This study represents a significant stride in precision oncology, where the nuanced understanding of protein structure and dynamics can lead to highly selective molecular interventions. It epitomizes the evolving interplay between AI and experiment—where computational hypotheses must be rigorously tested in the laboratory to unlock biomedical breakthroughs.

The work, published recently in the Journal of the American Chemical Society, titled “Allosteric Inhibition of PKMYT1 Induces a Unique, Inactive ATP Binding Site Conformation,” showcases the power of integrating modern AI tools with classical experimental techniques. It exemplifies a model for future drug discovery endeavors aiming to outpace cancer’s complexity through technological and scientific synergy.

As the scientific community digests these revelations, the broader implications are clear: protein targets once deemed structurally intractable may hide exploitable vulnerabilities, awaiting discovery through combined AI and experimental approaches. This challenges researchers to rethink strategies in drug design, moving toward a more dynamic and flexible framework to combat diseases with precision.

In summary, the Icahn School of Medicine’s team has not only unearthed a novel therapeutic target on a cancer-relevant kinase but also illuminated the frontiers and limitations of AI-driven drug discovery. Their pioneering work reinforces that while algorithms can guide drug development, the enduring rigor of experimental science remains critical to truly transformative medical advances.

---

Subject of Research: Cells

Article Title: Allosteric Inhibition of PKMYT1 Induces a Unique, Inactive ATP Binding Site Conformation

News Publication Date: June 3, 2026

Web References: http://dx.doi.org/10.1021/jacs.6c05178

References: Herrington, N. B., Khamrui, S., Zhao, Y., Lansiquot, C., Wu, R., Pandey, G., Lazarus, M. B., & Schlessinger, A. (2026). Allosteric Inhibition of PKMYT1 Induces a Unique, Inactive ATP Binding Site Conformation. Journal of the American Chemical Society. DOI: 10.1021/jacs.6c05178

Image Credits: Herrington, et al., Journal of the American Chemical Society

Keywords: Drug development, kinase inhibition, cancer therapy, AI drug discovery, protein dynamics, allosteric pocket, PKMYT1, molecular dynamics, AlphaFold, X-ray crystallography

The results were so promising one clinician started weeping.

In a groundbreaking advancement that could revolutionize the treatment landscape for synovial sarcoma, researchers have unveiled compelling evidence that Apatinib, a potent tyrosine kinase inhibitor, effectively halts tumor progression and angiogenesis through intricate modulation of critical signaling pathways. This discovery, detailed in a recent publication in Cell Death Discovery, shines a spotlight on the crucial role of VEGFR2-mediated AKT/FOXO3A and ERK1/2/FOXM1 signaling cascades, offering new hope against this notoriously aggressive and treatment-resistant soft-tissue malignancy.

Synovial sarcoma, characterized by its aggressive behavior and poor prognosis, poses significant clinical challenges due to its high metastatic potential and limited responsiveness to conventional chemotherapies. The current therapeutic arsenal frequently falls short, driving an urgent demand for targeted treatments that can disrupt the disease’s fundamental biology without imposing debilitating side effects. Apatinib, previously recognized for its efficacy in other solid tumors, emerges here as a formidable candidate, capable of interfering with angiogenesis and tumor growth at a molecular level.

The study pivots around the vascular endothelial growth factor receptor 2 (VEGFR2), a tyrosine kinase receptor implicated in angiogenesis—a pivotal process that tumors exploit to secure blood supply and nutrients essential for their survival and expansion. By selectively inhibiting VEGFR2, Apatinib impedes the downstream signaling networks that orchestrate cellular proliferation and neovascularization. This targeted blockade results in significant attenuation of tumor vascularization within synovial sarcoma models, effectively starving malignant cells and curtailing tumor growth.

Delving into the molecular intricacies, the research elucidates how Apatinib’s inhibition of VEGFR2 disrupts two critical intracellular signaling pathways: the AKT/FOXO3A axis and the ERK1/2/FOXM1 cascade. Both pathways are instrumental in regulating cell survival, apoptosis, and cell cycle progression, aspects that cancer cells hijack to forge their unchecked proliferation. The AKT pathway, frequently hyperactivated in cancers, phosphorylates FOXO3A, a transcription factor known for its tumor suppressor functions, thereby preventing FOXO3A from executing its role in promoting apoptosis and cell cycle arrest. Apatinib’s intervention restores FOXO3A activity, tipping the balance in favor of cell death and suppression of tumorigenesis.

Simultaneously, Apatinib impinges upon the ERK1/2/FOXM1 signaling axis. ERK1/2, members of the MAP kinase family, are critical regulators of cell division and differentiation. Their activation culminates in the induction of FOXM1, a transcription factor that drives the expression of genes essential for cell cycle progression and angiogenesis. Overexpression of FOXM1 has been documented in numerous malignancies, including synovial sarcoma, where it sustains proliferative signaling and confers resistance to apoptosis. The study reveals that Apatinib’s blockage of ERK1/2 phosphorylation leads to decreased FOXM1 expression, suppressing the pro-tumorigenic programs it controls.

Importantly, the researchers employed both in vitro and in vivo models to validate these findings, demonstrating consistency across experimental platforms. Synovial sarcoma cell lines exhibited marked declines in proliferation rates and angiogenic capacity upon Apatinib treatment, findings that were corroborated in animal models where tumor size and vascular density were significantly reduced. These multi-tiered validations underscore the translational potential of Apatinib, paving the way for clinical evaluation in synovial sarcoma patients.

Beyond tumor cells themselves, the study highlights the tumor microenvironment as a vital target of Apatinib’s action. Angiogenesis is orchestrated not solely by malignant cells but also by endothelial cells that constitute the vascular infrastructure. Apatinib’s inhibition of endothelial VEGFR2 hampers the formation of new blood vessels, which are essential conduits for tumor nourishment and metastatic dissemination. By disrupting this supportive niche, the therapy exerts comprehensive anti-cancer effects.

Equally intriguing is the potential impact on resistance mechanisms. Cancer frequently adapts to targeted therapies through activation of compensatory pathways, leading to relapse and treatment failure. The dual blockade of AKT/FOXO3A and ERK1/2/FOXM1 pathways by Apatinib suggests a multifaceted assault that minimizes escape routes for synovial sarcoma cells. This strategy may translate into durable responses and prolonged patient survival.

Mechanistically, the study delves into phosphorylation dynamics, transcriptional modulation, and feedback loops integral to cancer cell signaling. The interplay between phosphorylated AKT and FOXO3A dictates nuclear localization and transcriptional activity of the latter, while ERK1/2 phosphorylation governs the stability and transactivation function of FOXM1. Apatinib’s inhibition at these nodal points disrupts the finely tuned cellular machinery—a precision strike against malignancy.

Furthermore, the investigation raises important considerations regarding therapeutic dosing and scheduling to maximize efficacy while minimizing adverse effects. Pharmacokinetic analyses indicate that Apatinib maintains sustained inhibition of VEGFR2 and downstream kinases, supporting a feasible clinical regimen. Toxicity profiles gleaned from preclinical models suggest tolerability, an encouraging feature for patients who often endure debilitating side effects with conventional chemotherapy.

This research also opens avenues for combinational strategies. Given the complexity of cancer signaling networks, integrating Apatinib with agents targeting complementary pathways could potentiate anti-tumor effects and overcome resistance. Immunotherapeutic approaches, for instance, may synergize with Apatinib by further dismantling the tumor microenvironment and promoting immune-mediated clearance.

On a broader scale, these findings enhance our understanding of synovial sarcoma biology, underscoring the centrality of VEGFR2-mediated pathways in tumor progression and angiogenesis. This sets a precedent for further exploration of molecular drivers in rare and refractory cancers, facilitating tailored therapeutic approaches grounded in molecular pathology.

As the scientific community advances towards precision oncology, agents like Apatinib exemplify the paradigm shift from nonspecific cytotoxic drugs to targeted, mechanism-based therapies. The elucidation of signaling pathways critical to cancer cell survival forms the cornerstone of this transition, translating molecular insights into tangible clinical benefits.

The implications of this study resonate well beyond synovial sarcoma. VEGFR2-mediated pathways are implicated in a spectrum of malignancies, suggesting that Apatinib or similar agents could find utility across cancer types. The dual inhibition mechanism may also inspire the design of novel molecules capable of targeting multiple oncogenic pathways simultaneously.

In conclusion, the discovery that Apatinib effectively suppresses synovial sarcoma progression and angiogenesis by interfering with VEGFR2-driven AKT/FOXO3A and ERK1/2/FOXM1 signaling pathways marks a significant milestone in cancer research. The hope ignited by these findings galvanizes efforts towards clinical translation and heralds a new chapter in the management of synovial sarcoma, with the promise of improved outcomes for patients grappling with this formidable disease.

---

Subject of Research: Synovial sarcoma progression and angiogenesis inhibition via VEGFR2-mediated signaling pathways.

Article Title: Apatinib inhibits synovial sarcoma progression and angiogenesis via VEGFR2-mediated AKT/FOXO3A and ERK1/2/FOXM1 signaling pathways.

Article References:
Liu, R., Zhang, F., Shi, K. et al. Apatinib inhibits synovial sarcoma progression and angiogenesis via VEGFR2-mediated AKT/FOXO3A and ERK1/2/FOXM1 signaling pathways. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03188-7

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03188-7

In a significant development within the realm of nuclear medicine and molecular imaging, Dr. Gary Ulaner has been appointed as the president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). This appointment, announced during the SNMMI 2026 Annual Meeting held from May 30 to June 2 in Los Angeles, highlights the growing importance and transformative potential of nuclear medicine in contemporary healthcare. Dr. Ulaner’s expertise and leadership are poised to drive forward innovative research and clinical applications that could redefine patient care, particularly in oncology and molecular diagnostics.

Dr. Ulaner currently holds the James & Pamela Muzzy Endowed Chair of Molecular Imaging and Therapy at the Hoag Family Cancer Institute and serves as a Professor of Radiology and Translational Genomics at the University of Southern California. His multifaceted roles underscore a career dedicated to the integration of molecular imaging technologies and translational research, aligning with the broader goals of personalized medicine and precision oncology. His background exemplifies the merger of academic rigor and clinical application crucial for advancing this rapidly evolving field.

Nuclear medicine, a specialty focused on the use of radioactive substances in diagnosis and therapy, stands at the forefront of precision medicine innovation. The role of the president-elect extends beyond administrative leadership; it includes championing initiatives that fortify research infrastructures, expand educational platforms, and secure funding to nurture the next generation of radiochemistry and nuclear physics professionals. Dr. Ulaner’s vision emphasizes a holistic advancement, where technological innovation dovetails with workforce development and interdisciplinary collaboration.

Dr. Ulaner’s academic foundation was established at Stanford University School of Medicine, where he earned both his MD and PhD in Cancer Biology. His post-doctoral training involved rigorous residencies in Nuclear Medicine and Diagnostic Radiology at the University of Southern California. This robust training has empowered him with a unique perspective that bridges molecular imaging technology, radiopharmaceutical development, and clinical oncology, driving impactful translational research.

Before his current tenure at Hoag Family Cancer Institute, Dr. Ulaner was an Associate Member on a tenure track at Memorial Sloan Kettering Cancer Center—a leading institution in cancer research and treatment. At MSK, he developed significant academic and clinical roles that contributed to the institution’s pioneering work in PET imaging and molecular diagnostics. His professional credentials are further reinforced by certifications from the American Board of Radiology and the American Board of Nuclear Medicine, underscoring his specialized expertise.

Within the SNMMI, Dr. Ulaner has been an active and influential member, occupying vital leadership positions such as director at large on the board of directors, president of the PET Center of Excellence, and chair of the Mars Shot Campaign—a bold initiative aimed at advancing nuclear medicine research. His multifaceted involvement signals his commitment to driving SNMMI’s strategic objectives, including the formulation of standards, educational outreach, and advocacy for nuclear medicine’s value in clinical practice.

His scholarly contributions are substantial, with over 190 journal articles and more than 300 invited presentations. Dr. Ulaner has contributed to seminal guidelines such as SNMMI’s Appropriate Use Criteria for Fluoroestradiol PET, setting standards that influence clinical decision-making globally. His editorial roles and authorship of textbooks like “Fundamentals of Oncologic PET/CT” demonstrate his dedication to disseminating knowledge and fostering an educated workforce proficient in advanced imaging modalities.

The Mars Shot Campaign, under Dr. Ulaner’s leadership, exemplifies a visionary approach to accelerating research and innovation within nuclear medicine. This initiative targets critical translational gaps, funding high-impact projects that aim to develop novel radiopharmaceuticals and imaging technologies with the potential to revolutionize diagnostic accuracy and therapeutic efficacy. Such efforts are crucial in overcoming existing limitations related to imaging biomarkers and personalized treatment monitoring.

Dr. Ulaner’s dedication to education and training extends beyond research innovation. He actively advocates for expanding educational opportunities for nuclear medicine professionals—technologists, clinicians, physicists, and radiochemists—recognizing the interdisciplinary nature of the field. This approach is vital for sustaining a skilled workforce capable of navigating the complexities of molecular imaging and theranostics, transforming patient outcomes in oncology and other disease domains.

Throughout his career, Dr. Ulaner has garnered numerous accolades, including the Susan G. Komen Career Catalyst Award and the Department of Defense Breakthrough Award. His recognition as a Distinguished Investigator by the Academy for Radiology & Biomedical Imaging Research and as a healthcare visionary highlights both his scientific contributions and leadership qualities. Such honors reflect his role as a catalyst for innovation at the interface of cancer biology, imaging science, and clinical oncology.

The SNMMI’s election of new officers alongside Dr. Ulaner—Heather Jacene, MD as president and Jason S. Lewis, PhD as vice president-elect—illustrates a leadership cohort poised to navigate the next frontier of nuclear medicine. Their collective expertise underscores the society’s commitment to fostering cutting-edge research, expanding educational horizons, and enhancing policy frameworks to elevate the role of molecular imaging in modern medicine.

As president-elect, Dr. Ulaner’s agenda will involve steering the SNMMI to harness the full potential of nuclear medicine and molecular imaging technologies. These advancements promise not only to enhance the early detection and characterization of malignancies but also to optimize individualized therapy through theranostics—combining targeted diagnostics with personalized treatment regimens. This paradigm shift aligns closely with contemporary trends aimed at achieving superior patient outcomes through precision health strategies.

The Society of Nuclear Medicine and Molecular Imaging remains at the vanguard of scientific and medical innovation, dedicated to advancing nuclear medicine, molecular imaging, and theranostics worldwide. Dr. Ulaner’s ascension to the role of president-elect represents a pivotal moment in reinforcing the society’s mission. His leadership is expected to invigorate research efforts, expand educational initiatives, and advocate for policies that solidify the critical role of molecular imaging in the healthcare continuum, driving transformative advances for patients globally.

Subject of Research:
Nuclear medicine, molecular imaging, and theranostics with a focus on oncologic PET/CT and translational genomics in cancer care.

Article Title:
Gary Ulaner, MD, PhD, Named President-Elect of the Society of Nuclear Medicine and Molecular Imaging, Heralding New Era in Molecular Imaging and Theranostics

News Publication Date:
June 7, 2026

Web References:
http://www.snmmi.org/

Image Credits:
Courtesy of SNMMI

Keywords:
Molecular imaging, Nuclear medicine, Positron emission tomography (PET), Personalized medicine, Theranostics, Oncology imaging, Radiopharmaceuticals, Translational genomics, SNMMI, PET/CT, Radiochemistry, Molecular diagnostics

The results were so promising one clinician started weeping.

The results were so promising one clinician started weeping.

Clinical trials in China are getting attention at an international oncology gathering in Chicago. China’s surging biotechnology industry is fueling alarm that U.S. dominance in the field is waning.

A groundbreaking advancement in the realm of metastatic castration-resistant prostate cancer (mCRPC) therapy has emerged from a recent study involving machine learning and molecular imaging. Researchers have developed an innovative predictive model capable of estimating the radiation dose that tumors and critical organs might absorb during ^177Lu-PSMA radiopharmaceutical therapy, a leading treatment modality for mCRPC. This pioneering approach leverages data derived from pre-therapy ^18F-PSMA PET/CT scans, fundamentally transforming treatment planning by enabling more accurate, patient-specific predictions prior to the commencement of therapeutic intervention.

Dosimetry—the precise measurement of absorbed radiation dose—remains an indispensable component in refining and optimizing radionuclide therapies such as ^177Lu-PSMA. Traditionally, dosimetric evaluation relies heavily on imaging conducted post-treatment, which poses significant challenges due to its labor-intensive nature and the extensive resources required. The advent of a pre-therapy predictive tool utilizing widely available ^18F-PSMA PET/CT imaging represents a major leap forward by potentially circumventing these constraints. This shift not only promises to streamline clinical workflows but also extends the possibility of tailoring treatment intensity to individual patient profiles, thus maximizing therapeutic benefit while minimizing adverse effects.

The research, spearheaded by Dr. Amit Nautiyal and colleagues at the University Hospital Southampton and the University of Southampton, UK, employs a sophisticated machine learning framework combining mixed-effects modeling with multi-parametric data inputs. The model assimilates PET uptake metrics, radiomic features—which capture spatial and textural heterogeneity of lesions—and relevant clinical biomarkers. By integrating these multidimensional variables, the algorithm can accommodate inter-patient variability and predict absorbed dose distributions in tumors alongside vital organs such as salivary glands and kidneys with promising accuracy.

This proof-of-concept study analyzed data from nine mCRPC patients undergoing ^177Lu-PSMA therapy. Across these individuals, 57 tumors, 36 salivary glands, and 18 kidneys were evaluated, offering a robust dataset for model training and validation. The comparison of predicted absorbed doses with those calculated via conventional post-therapy imaging demonstrated the model’s potential in accurately forecasting dosimetric outcomes prior to treatment initiation. Such validation underscores how comprehensive image-derived quantitative features, when harnessed through machine learning techniques, can revolutionize personalized treatment planning in nuclear medicine.

One of the critical advantages of this approach lies in its capacity to inform patient selection. By predicting which patients are likely to receive optimal radiation doses in tumors while sparing normal tissue, clinicians can better stratify candidates for ^177Lu-PSMA therapy. This strategic selection inherently reduces the risk of treatment-associated toxicity and enhances the likelihood of favorable clinical responses. Furthermore, this predictive capacity may serve as an invaluable decision support tool during multidisciplinary team discussions, where tailored therapeutic regimens are formulated based on individual risk-benefit assessments.

The integration of radiomics—a burgeoning field that quantitatively analyzes medical images beyond conventional visual interpretation—marks a significant step forward in nuclear oncology. The nuanced information extracted from texture, shape, and intensity patterns within the ^18F-PSMA PET/CT images provides a rich dataset that machine learning algorithms can exploit to uncover complex relationships correlating with dosimetric parameters. When combined with patient-specific clinical biomarkers, this multifaceted modeling embodies the essence of precision medicine, ensuring treatment is dynamically adapted to each patient’s unique biological landscape.

Dr. Nautiyal emphasizes the transformative potential of this methodology, suggesting that, pending corroboration through larger cohort studies, it could redefine pre-treatment assessment strategies globally. Such validation would not only affirm the reproducibility and scalability of the model but also encourage its adoption into routine clinical practice. The ability to anticipate radiation dose distributions before therapy confers tangible benefits, including reduced need for extensive post-therapy imaging, diminished patient burden, and expedited initiation of treatment cycles.

The current research represents a foundational step in a comprehensive five-year initiative aimed at expanding the training dataset, refining the predictive accuracy of the model, and conducting rigorous external validation using multi-center patient cohorts. This longitudinal program aspires to establish a robust, clinically deployable tool capable of stratifying patients effectively and personalizing ^177Lu-PSMA radiopharmaceutical therapy. Importantly, the ongoing collaboration across institutions highlights the multidisciplinary nature of this endeavor, spanning nuclear medicine, radiology, oncology, and data science.

From a technical perspective, the employment of mixed-effects models within the machine learning framework allows for the accommodation of both fixed effects related to PET and clinical features and random effects capturing patient-specific variabilities. This statistical architecture enhances the model’s flexibility and adaptability across heterogeneous patient populations, which is paramount given the variability inherent in tumor biology and organ susceptibility. It also mitigates potential biases that might arise from limited sample sizes, fostering generalizability.

The implications of this work extend beyond prostate cancer and ^177Lu-PSMA therapy. The demonstrated feasibility of using pre-treatment imaging combined with advanced computational analytics to predict treatment dosimetry could inspire similar approaches across various theranostic applications. This positions imaging not merely as a diagnostic modality but as a dynamic, integral component of personalized therapy planning, bridging the gap between molecular visualization and actionable clinical insights.

In conclusion, this compelling study from the University of Southampton consortium delivers a visionary framework for enhancing the precision and efficacy of radionuclide therapy in advanced prostate cancer. By harnessing routinely acquired ^18F-PSMA PET/CT data through machine learning innovation, the research charts a path toward individualized treatment strategies that promise to improve patient outcomes significantly. As this technology progresses toward clinical translation, it heralds a paradigm shift in nuclear medicine, where therapy is foreseen and optimized well before a radioactive agent is administered.

Subject of Research: Machine learning for pre-therapy prediction of tumor and organ absorbed dose in ^177Lu-PSMA radiopharmaceutical therapy using ^18F-PSMA PET/CT radiomics and clinical biomarkers.

Article Title: Machine Learning-Based Pretherapy Prediction of Tumor and Organ Absorbed Dose in ^177Lu-PSMA Therapy Using ^18F-PSMA PET/CT Radiomics and Biomarkers

News Publication Date: 2026 (presented at SNMMI 2026 Annual Meeting)

Web References:

• Link to Abstract
• Society of Nuclear Medicine and Molecular Imaging official site: snmmi.org

References:

• Nautiyal A., Crabb S., Martinez Camacho R., Sundram F., Saad Z., Michopoulou S., Dewaraja Y., Dickson J. Machine Learning-Based Pretherapy Prediction of Tumour and Organ Absorbed Dose in ^177Lu-PSMA Therapy Using ^18F-PSMA PET/CT Radiomics and Biomarkers. SNMMI 2026 Annual Meeting, Abstract 262138.

Image Credits: Courtesy of SNMMI

Keywords: molecular imaging, positron emission tomography, radiopharmaceutical therapy, prostate cancer, ^177Lu-PSMA therapy, ^18F-PSMA PET/CT, dosimetry, machine learning, radiomics, personalized medicine, metastatic castration-resistant prostate cancer, nuclear medicine